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Abstract
Background: TRPM8 is a non-selective cation channel that belongs to the melastatin subfamily of
the transient receptor potential (TRP) ion channels. TRPM8 is activated by voltage, cold and cooling
compounds such as menthol. Despite its essential role for cold temperature sensing in mammals,
the pharmacology of TRPM8 is still in its infancy. Recently, tyrosine 745 (Y745) was identified as a
critical residue for menthol sensitivity of the channel. In this report, we study the effect of mutating
this residue on the action of several known TRPM8 antagonists: BCTC, capsazepine, SKF96365, and
clotrimazole as well as two new inhibitor candidates, econazole and imidazole.
Results: We show that Y745 at the menthol binding site is critical for inhibition mediated by
SKF96365 of cold- and voltage-activated TRPM8 currents. In contrast, the inhibition by other
antagonists was unaffected by the mutation (BCTC) or only partially reduced (capsazepine,
clotrimazole, econazole), suggesting that additional binding sites exist on the TRPM8 channel from
where the inhibitors exert their negative modulation. Indeed, a molecular docking model implies
that menthol and SKF96365 interact readily with Y745, while BCTC is unable to bind to this
residue.
Conclusion: In summary, we identify structural elements on the TRPM8 channel that are critical
for the action of channel antagonists, providing valuable information for the future design of new,
specific modulator compounds.
Background
TRPM8 is a non-selective cation channel of the TRP family
that is activated by mild cold temperatures and cooling
compounds such as menthol, eucalyptol and icilin [1,2].
Like several other TRP channels, TRPM8 is also gated by
voltage [3-6]. The voltage dependence of TRPM8 is char-
acterised by a strong outward rectification at depolarized
transmembrane potentials, and a rapid and potential-
dependent closure at negative membrane potentials.
Cooling and menthol application shift the activation
curve of TRPM8 towards more negative potentials, thus
increasing the probability of channel openings, boosting
inward currents at physiological membrane potentials [6].
Endogenous factors such as phospholipase A2 products
Published: 3 November 2009
Molecular Pain 2009, 5:62 doi:10.1186/1744-8069-5-62
Received: 25 August 2009
Accepted: 3 November 2009
This article is available from: http://www.molecularpain.com/content/5/1/62
© 2009 Malkia et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 13
(page number not for citation purposes)
Molecular Pain 2009, 5:62 http://www.molecularpain.com/content/5/1/62[7,8], endocannabinoids [9] and PIP2 [10-12] also partic-
ipate in channel regulation.
TRPM8 is expressed in a subset of small diameter primary
sensory neurons and their peripheral terminals [13,1,2].
In addition to its well characterized and critical role in the
activation of low threshold thermoreceptors, responsible
for the sensations of innocuous cold [14-16], other evi-
dence indicates the possible involvement of TRPM8 chan-
nels in normal noxious cold sensations and cold
allodynia [reviewed by [17]]. Notably, in an animal
model of neuropathic pain, cold allodynia is significantly
attenuated by capsazepine, a TRPM8 blocker [18], and
mice lacking TRPM8 show reduced responses in nerve
injury induced models of cold-allodynia [15,16]. Also,
sensory fibers with high threshold cold-evoked responses
are difficult to record from in these mice [14]. Moreover,
TRPM8-positive fibers are prominent in peripheral territo-
ries with marked noxious responses to cold [19]. Many
neurons responding to TRPM8 agonists are also activated
by capsaicin, a marker of nociceptors [20-22]. These new
findings stress the potential use of TRPM8 modulators in
the therapeutic management of cold-evoked pain, a char-
acteristic symptom in some patients with neuropathic
pain [23].
Despite its fundamental role in many aspects of cold tem-
perature transduction in mammals, the pharmacology of
TRPM8 is still largely unexplored. Only a few studies have
so far been dedicated to TRPM8 channel inhibitors and
their mechanisms of action [24-30]. Recently, Malkia et al.
[26] showed that several antagonist compounds, includ-
ing BCTC and SKF96365, act as negative allosteric modu-
lators of channel gating, shifting the voltage activation of
TRPM8 towards more positive potentials, suppressing the
depolarizing effects of temperature and chemical agonists
[25,26]. SKF96365 is a non-specific blocker of various cal-
cium-permeable channels, including receptor-operated
channels [31]. BCTC was originally introduced as a highly
potent and specific antagonist of the heat-activated vanil-
loid receptor TRPV1 [32]. However, later studies showed
that it also inhibits the TRPM8 channel, as does another
TRPV1 blocker, capsazepine [24,26,29]. These two antag-
onists bind competitively at the vanilloid binding pocket
of the TRPV1 channel, governed by residues in the intrac-
ellular parts of the putative transmembrane domains 2, 3
and 4 [33,34].
Recently, during a massive random mutagenesis screen,
tyrosine 745, located in the middle of putative transmem-
brane segment 2, was identified as a crucial residue for the
menthol sensitivity of mouse TRPM8 [35]. The generated
TRPM8-Y745H mutant channel was insensitive to men-
thol, but retained the responsiveness to cold and voltage
exhibited by the wild-type channel. Because of the signif-
icant parallels between TRPM8 and TRPV1 pharmacology
[24,29], we decided to study the effect of the Y745H muta-
tion on the activity of the best characterized TRPM8 antag-
onists: BCTC, capsazepine, SKF96365 and clotrimazole,
as well as of two new inhibitor candidates: econazole and
imidazole. We identify, for the first time, structural ele-
ments on the TRPM8 protein that are critical for channel
antagonism, and demonstrate an important difference in
the way antagonists interact with the menthol binding site
of TRPM8.
Results
Expression and functional phenotype of the TRPM8-
Y745H mutant
The correct expression of the TRPM8-Y745H mutant was
first verified by Western blot analysis of lysates from
HEK293 cells transfected with the TRPM8-wt and TRPM8-
Y745H plasmids. The TRPM8 antibody strongly detected
both the wild-type and the mutant constructs at the
expected size of 130 kDa (Figure 1A).
Next, the functionality of the TRPM8-Y745H mutant was
investigated employing the calcium imaging technique.
All GFP expressing cells exhibited robust responses to
cooling of the bath solution, indicative of the presence of
a cold-sensitive TRPM8 variant (Fig. 1B-C). However, only
in TRPM8-wt transfected cells did 100 μM menthol
increase the intracellular calcium levels when applied at
33°C or during cooling. The lack of menthol responses of
the Y745H mutant was also confirmed with whole-cell
electrophysiological recordings, which showed that the
Y745H mutant channel was completely insensitive to
menthol at all potentials (Fig. 2A-B). Both, the calcium
imaging and the electrophysiological recordings con-
firmed the critical role of Y745 in menthol-dependent
activation of TRPM8 [35].
Next, to investigate whether the mutation at the Y745 res-
idue affected the voltage-dependent channel gating we
performed a detailed analysis of the I-V curves obtained
from -100/+150 mV voltage ramps by fitting them to
equation (i) under different agonist conditions. As seen in
Figures 2C-E, no differences in the cold-induced increase
in maximum conductance, gcold/gctrl, or shift in midpoint
voltage of activation, ΔV1/2, were observed between the
wild-type channel and the Y745H mutant, whereas a clear
difference was present when menthol was used as the ago-
nist. The absolute value of V1/2 during cooling was like-
wise similar in the wild-type and mutant channels (wt: 83
± 6 mV, n = 19 vs. Y745H: 76 ± 11 mV, n = 14; unpaired t-
test; p = 0.56).
The apparent gating charge, zapp, was slightly lower in the
Y745H mutant compared with the wild-type during con-
trol and cooling conditions. While menthol decreased thePage 2 of 13
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nel gating charge was unaffected. When we compared the
I-V parameters of the Y745H mutant during applications
of cold and cold plus menthol, no difference was observed
indicating that the Y745 residue also perfectly accounts
for any sensitizing effect that menthol has on the cold
response (paired t-test; p > 0.05; n = 6).
Sensitivity of the TRPM8-Y745H mutant to BCTC, 
SKF96365, capsazepine and clotrimazole
We next proceeded to investigate the ability of several
known TRPM8 antagonists to block the TRPM8-Y745H
mutant channel during activation by cold. In Figure 3 and
Table 1, the structures of the blockers and their half max-
imal inhibitory concentrations at the wild-type channel
are given. Dose-inhibition curves of BCTC and SKF96365
at the cooling-activated wild-type channel have been pub-
lished previously [26]. Calcium imaging experiments
revealed that the mutation affected the ability of the
antagonists to inhibit TRPM8 activity to a varying extent.
While BCTC maintained its full and reversible blocking
potential when tested on the Y745H mutant (Figures 4A,
C, E), SKF96365, applied at the saturating dose of 3 μM,
exhibited a nearly complete loss of effect (Figures 4B, D,
E). To determine whether the observed lack of block at the
mutant channel was due to a shift in the dose-response
curve of SKF96365, we also tested a super saturating con-
centration of the drug. However, 20 μM SKF96365 (n =
13) was unable to increase block of the cold-evoked
response compared with 3 μM of the antagonist (Figure
4E), confirming the complete insensitivity of the Y745H
mutant to this compound.
Two other compounds with reported TRPM8 antagonism,
capsazepine and clotrimazole, both lost part of their
inhibitory potential at the Y745H mutant. As seen in Fig-
ures 5A, B, E, the effect of the mutation was to decrease the
potency of these compounds compared with the wild-
type channel and to shift their dose-inhibition curves
towards higher concentrations. Clotrimazole exhibits lim-
ited solubility in the extracellular solution used, and
obtaining reproducible data above 20 μM was compli-
cated, especially for the Y745H mutant channel where the
dose-inhibition curve was in its steepest phase.
The TRPM8-Y745H mutant is insensitive to menthol, but retains cold sensitivityFigure 1
The TRPM8-Y745H mutant is insensitive to menthol, but retains cold sensitivity. A, Western blot where the lanes 
represent lysates of HEK293 cells transfected with TRPM8-wt and TRPM8-Y745H. B, Representative traces showing calcium 
imaging experiments of HEK293 cells expressing TRPM8-wt or TRPM8-Y745H. Note that only the cells expressing TRPM8-wt 
respond to menthol. C, Summary histogram of experiments seen in B. Intracellular calcium increases were compared using 
repeated-measures 2-way ANOVA in combination with Bonferroni's post test with respect to the effect of the mutation on 
each condition: *** p < 0.001; n = 14 (TRPM8-wt) and n = 19 (TRPM8-Y745H).
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Molecular Pain 2009, 5:62 http://www.molecularpain.com/content/5/1/62In view of the recent discovery of the inhibitory activity of
the imidazole derivatives SKF96365 [31] and clotrima-
zole at the TRPM8 channel [26,27], we decided to investi-
gate the antagonism of two structurally related
compounds, the parent compound imidazole and the
antimycotic agent econazole. Similarly to clotrimazole,
econazole is an effective antagonist of TRPM2 [36], and
has also been reported to potently block TRPV5 channels
(ECaC1) [37]. We found that econazole was even more
potent than clotrimazole at the wild-type TRPM8 channel
as measured by calcium imaging (Figures 5C, E), exhibit-
ing an IC50 of 0.42 ± 0.07 μM (n = 9-33). Similarly to clot-
rimazole, the antagonism of econazole was significantly
reduced at the Y745H mutant channel (Figure 5C, E). Imi-
dazole, on the other hand, was ineffective at both the
TRPM8 wild-type and Y745H mutant channels, at concen-
trations of 20 μM, 100 μM and 1 mM (Figure 5D).
While the TRPM8-wt channel is known to undergo certain
rundown in the experimental conditions used in our cal-
cium imaging recordings [26], the almost complete recov-
ery of the initial cooling response after 3 minutes of
washing observed with the majority of the antagonists
(e.g. Figure 4) demonstrates the inhibition to be specific
to the antagonists applied.
Electrophysiological characterization of TRPM8-Y745H mutant sensitivity to menthol, cold and voltageFigu e 2
Electrophysiological characterization of TRPM8-Y745H mutant sensitivity to menthol, cold and voltage. A, 
Whole-cell current-voltage relationships of TRPM8-wt and TRPM8-Y745H expressing HEK293 cells in control and menthol-
containing solutions at 33°C. Note the different current scale. B, Summary histogram of experiments seen in A showing men-
thol-induced whole-cell currents at various potentials, normalized with the current in control conditions. Note the logarithmic 
current scale. The responses of TRPM8-wt vs. Y745H were compared with repeated-measures 2-way ANOVA in combination 
with Bonferroni's post test with respect to the effect of the mutation at each potential: *** p < 0.001; * p < 0.05; n = 7 
(TRPM8-wt) and n = 13 (TRPM8-Y745H). C-E, Parameters obtained from fits of I-V data of experiments such as the ones 
showed in A to equation (i), n = 4-19. C, Average values of the apparent gating charge in control (33°C), menthol (100 μM), 
cooling (20°C) and cooling + menthol, of the TRPM8-wt vs. TRPM8-Y745H. D, Average maximum conductance (g) of cells 
expressing TRPM8-wt and TRPM8-Y745H during cooling and menthol application. The data are normalized with the value of g 
of the same cells in control solution at 33°C. E, Agonist-induced shifts of the midpoint of voltage activation (V1/2) of TRPM8-wt 
vs. TRPM8-Y745H. The data are represented with respect to the value of V1/2 in control solution at 33°C. In panels C-E, statis-
tical significance was assessed with Student's unpaired t-test: *** p < 0.001; ** p < 0.01; * p < 0.05.
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Molecular Pain 2009, 5:62 http://www.molecularpain.com/content/5/1/62Electrophysiology confirms the differential effects of the 
Y745H mutation on BCTC and SKF96365 antagonism
In a previous study we showed that calcium imaging pro-
vides a reliable estimate of the potency of block of TRPM8
by different antagonists [26]. Nevertheless, in order to
assess channel function directly and obtain more detailed
information on the mechanism of block, we subsequently
employed the whole-cell patch clamp technique. We
focused on BCTC and SKF96365 because they showed the
largest differences between wild-type and mutant chan-
nels. Figure 6A shows I-V curves of the wild-type and
Y745H mutant channels during cooling of the divalent-
free bath solution in the presence and absence of 0.6 μM
BCTC. This lower concentration was chosen so as to
obtain more reliable fits to equation (i), and to detect pos-
sible dose-response effects not seen with the saturating
concentration of 3 μM. Analysis of the I-V curves shows
that the Y745H mutant channel exhibits a similar
response to BCTC at +80 mV when compared with the
wild-type channel (Figure 6C). Furthermore, fits of the
curves to equation (i) during activation by cold, allowed
us to confirm our previous observation [26] that BCTC
inhibits TRPM8 channel activity through a reduction in
maximum conductance and a shift of the midpoint activa-
tion voltage towards more positive potentials. No signifi-
cant differences were observed in either of these
Table 1: Summary of inhibition of the TRPM8-wt channel.
Compound IC50 cold (μM) IC50 menthol (μM)
BCTC 0.68 ± 0.06a (CI)
0.54 ± 0.04a (EP)
0.47 ± 0.01b (CI)
0.34 ± 0.04b (EP)
SKF96365 1.0 ± 0.2a (CI)
0.8 ± 0.1a (EP)
3 ± 1b (CI)
Capsazepine 12 ± 2d (CI) 18 ± 1c (FLIPR)
Clotrimazole 8 ± 1d (CI) 1.2e (EP)
Econazole 0.42 ± 0.07d (CI) N/A
Imidazole >> 1000 N/A
Inhibitory potency of various blockers at the cold- or 100 μM 
menthol-activated TRPM8-wt channel as measured by calcium imaging 
(CI), a fluorometric imaging plate reader assay (FLIPR) or 
electrophysiology (EP). Data are from: a[26]; bmodified from [25]; 
c[24]; dthis work; e[27]. Whole-cell patch-clamp data are given at +80 
mV, except for e, where the block was estimated at +50 mV.
Structures of the various TRPM8 antagonists and mentholFigure 3
Structures of the various TRPM8 antagonists and menthol. Chemical structures of the various antagonists tested at 
the TRPM8-wt and Y745H mutant channels. The structure of menthol is shown for comparison.
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Molecular Pain 2009, 5:62 http://www.molecularpain.com/content/5/1/62parameters between the wild-type channel and the Y745H
mutant (Figures 6D-E), nor in the apparent gating charge
(not shown). The effects were dose-dependent and readily
reversible upon wash of the drug (Figure 6A). At 3 μM,
BCTC blocked 98% of the cooling-activated TRPM8-
Y745H current at +80 mV (not shown).
In close agreement with the calcium imaging experiments,
3 μM SKF96365 exhibited potent antagonism of the wild-
type channel, but completely failed to block the cold-
evoked activation of the TRPM8-Y745H mutant (Figures
6B-C). Fits to equation (i) revealed that, in contrast to the
wild-type channel, in the mutant SKF96365 did not
reduce the maximum conductance from the value
obtained during cooling in control solution. Likewise the
V1/2 value of channel activation during cooling did not
shift with application of SKF96365 (Figures 6D-E). The
apparent gating charge during SKF96365 application was
similar in the wild-type and mutant channels (0.73 ± 0.04
vs. 0.63 ± 0.04, respectively, p = 0.25). No dose-depend-
ence was observed as 20 μM SKF96365 also lacked any
inhibitory effects (not shown).
The differential effects of the Y745H mutation on BCTC
and SKF96365 antagonism during cooling were also
observed at 33°C, a condition were TRPM8 is only acti-
Differential effect of the Y745H mutation on the antagonism of TRPM8 by BCTC and SKF96365Figu  4
Differential effect of the Y745H mutation on the antagonism of TRPM8 by BCTC and SKF96365. A-B, Cold-
evoked [Ca2+]i responses in HEK293 cells expressing TRPM8-wt or TRPM8-Y745H channels, showing the inhibition by A, 3 μM 
BCTC, and B, 3 μM SKF96365. C-D, Summary histograms of the [Ca2+]i responses of TRPM8-wt and TRPM8-Y745H channels 
to repeated cooling stimuli in the absence and presence of C, 3 μM BCTC (n = 9/11 wt/mut); and D, 3 μM SKF96365 (SKF; n = 
33/47). Note the reversible nature of the inhibition. E, Comparison of block of TRPM8-wt vs. TRPM8-Y745H by BCTC and 
SKF96365. In panels C-E, intracellular calcium increases were normalized to the first cold application in control solution. In 
panel E, the block of each antagonist condition was compared between TRPM8-wt and -Y745H using Student's unpaired t-test: 
*** p < 0.001; ns. = not significant. The block by 20 μM SKF96365 over the Y745H mutant is included to show the complete 
lack of inhibition.
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Molecular Pain 2009, 5:62 http://www.molecularpain.com/content/5/1/62vated by voltage [6]. In wild-type channels, BCTC and
SKF96365 produced a strong inhibition of the voltage-
activated current (Figure 7). In contrast, the Y745H muta-
tion fully abrogated the inhibition produced by
SKF96365 without affecting the block by BCTC.
Molecular simulations support the interaction between 
SKF96365 and Y745
To support the experimental data, we probed the docking
of menthol, BCTC and SKF96365 at a TRPM8 model pro-
tein (Figure 8). Menthol readily interacted with the Y745
binding site, disrupting the potentially stabilizing interac-
tions between this S2 residue and the D802 motif located
on S3 as already suggested by Pedretti et al. [38]. Further-
more, SKF96365 exhibited strong interactions with Y745,
while BCTC was unable to bind to this residue.
Discussion
In light of the potential involvement of TRPM8 channels
in the pathophysiology of cold nociception and cold allo-
dynia [reviewed by [17]], there is a strong interest in the
pursuit of novel modulators of TRPM8 channels. In this
study, we investigated the effect of different compounds at
the TRPM8-Y745H mutant channel, focusing on the dif-
ferential effects of several antagonists on the gating prop-
erties.
Cold and menthol activate wild-type TRPM8 by shifting
its voltage-dependent activation towards more negative
potentials [3,6]. We confirmed a previous report showing
that the tyrosine at position 745, on the putative S2 trans-
membrane segment, is essential for the agonist effects of
menthol [35]. Menthol is a small and fairly lipophilic
compound which easily partitions in the lipid bilayer and
could thus be expected to affect TRPM8 channel function
Variable inhibition of the Y745H mutant channel by capsazepine, clotrimazole, econazole and imidazoleFigure 5
Variable inhibition of the Y745H mutant channel by capsazepine, clotrimazole, econazole and imidazole. A-D, 
Dose-inhibition curves of various antagonists at the cooling-activated TRPM8-wt and TRPM8-Y745H channels: A, capsazepine 
(n = 17-23/13-29 wt/mut); B, clotrimazole (n = 7-17/12-25); C, econazole (n = 14-27/9-27); and D, imidazole (n = 12-21/13-16). 
E, Comparison of the IC50 of block of TRPM8-wt vs. TRPM8-Y745H by the above antagonists: capsazepine (CPZ); clotrimazole 
(CLOT); econazole (ECO). In panels A-D, the red traces represent the fits to the Hill equation. Error bars were used as 
weights in fitting. At each concentration, the block was compared between TRPM8-wt and -Y745H using Student's unpaired t-
test, and indicated where significant by: *** p < 0.001; ** p < 0.01; * p < 0.05.
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Molecular Pain 2009, 5:62 http://www.molecularpain.com/content/5/1/62from various interaction sites. However, during menthol
application to the menthol-insensitive TRPM8-Y745H
mutant, the parameters describing voltage gating: V1/2 and
g/gctrl underwent no changes whatsoever, suggesting that
menthol exerts its full effect by specific interaction with
the binding site governed by the tyrosine residue 745. In
the absence of menthol, the apparent gating charge, zapp,
was slightly lower in the TRPM8-Y745H mutant, indicat-
ing that this site is to some extent communicated with the
voltage sensor of the channel. This finding is supported by
recent work on TRPM8 voltage sensor mutants [39] and a
fragmental model of the channel structure [38].
While TRPM8 and TRPV1 share only around 20% protein
sequence homology [2], the channels have several pheno-
typic characteristics in common. Both are activated by
temperature changes, and C-terminal chimeras between
the channels exhibit reversed temperature sensitivity [40].
Furthermore, both TRPM8 and TRPV1 are inhibited by
compounds such as BCTC, CTPC, SB-452533, cap-
sazepine and ruthenium red [24,29]. All TRPV1 antago-
nists, with the exception of pore blockers such as
ruthenium red, seem to bind at the vanilloid binding
pocket [41]. However, no reports exist on the binding site
of TRPM8 antagonists.
In this study, we demonstrate the variable inhibitory effect
of several compounds at the TRPM8-Y745H mutant chan-
nel. This finding is unexpected since all of them affect gat-
ing of the channel in a similar fashion, shifting voltage-
Electrophysiology confirms the differential effects of the Y745H mutation on BCTC and SKF96365 antagonismFigu e 6
Electrophysiology confirms the differential effects of the Y745H mutation on BCTC and SKF96365 antago-
nism. Whole-cell I-V curves from voltage ramps (-100/+150 mV) of TRPM8-wt and TRPM8-Y745H expressing HEK293 cells 
during cooling in the presence and absence of A, 0.6 μM BCTC; and B, 3 μM SKF96365. Wash traces recorded 3 minutes after 
removal of the antagonist from the bath are included to show the reversible nature of the inhibition. C, Summary histogram of 
experiments depicted in A and B, showing the block of cold-evoked currents by 0.6 μM BCTC and 3 μM SKF96365 at a mem-
brane potential of +80 mV. D-E, Parameters obtained from fits of I-V data to equation (i). D, Antagonist-induced change in max-
imum conductance during cooling in cells expressing TRPM8-wt and TRPM8-Y745H. The data are normalized to the value 
during cooling in control solution of the same cells, (gcold+blocker/gcold). E, Antagonist-induced shifts of the midpoint of voltage 
activation (V1/2) of TRPM8-wt vs. TRPM8-Y745H during cooling. The data are represented with respect to the value of V1/2 in 
the absence of blocker (ΔV1/2 = V1/2, cold+blocker - V1/2, cold). In panels C-E, statistical significance was assessed with Student's 
unpaired t-test, n = 2-6.
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Molecular Pain 2009, 5:62 http://www.molecularpain.com/content/5/1/62dependence to more positive potentials and exerting an
allosteric negative modulation of the channel during cold-
or chemically evoked activation [26]. Our results reveal
that the tyrosine residue 745 at the menthol binding site
is critical for inhibition mediated by SKF96365. In con-
trast, the inhibition by other antagonists is unaffected
(BCTC) or only partially reduced (capsazepine, clotrima-
zole, econazole) by the mutation, suggesting that at least
one other binding site exists on the TRPM8 channel from
where the inhibitors exert their negative allosteric modu-
lation. Furthermore, the results imply that not all TRPM8
blockers should be considered competitive antagonists of
menthol, even though the allosteric inhibitory effect they
mediate lies in competition with the activating effect of
cooling agents [26].
The experimental observations of differential interaction
of Y745 with the antagonists SKF96365 and BCTC were
further confirmed by molecular docking studies. Interest-
ingly, in these simulations SKF96365 exhibited strong
interactions with both Y745 and an asparagine residue,
N799, that also interacts with icilin [42]. Looking at Fig-
ure 8C, SKF96365 can be hypothesized to lock the S2 and
S3 domains into a fixed position, thereby preventing con-
formational shifts of the S4 domain induced by menthol
(or cooling) that would lead to channel activation. This
idea is further supported by our finding that SKF96365
inhibits the TRPM8-wt current at 33°C, a condition in
which the channel is only activated by voltage, whereas no
effect is seen at the Y745H mutant. BCTC, in contrast,
blocks both the wild-type and mutant channels in this
condition with similar potency, indicating the presence of
an alternative binding site. Overall, our data suggest a
sequential model of TRPM8 gating where chemical mod-
ulators can favour (e.g. menthol) or hinder (e.g. BCTC or
SKF96365) the energetics of subsequent channel opening
by cold temperature or voltage, from different binding
sites.
Differential block of voltage-activated TRPM8-Y745H by BCTC and SKF96365Figu  7
Differential block of voltage-activated TRPM8-Y745H by BCTC and SKF96365. Whole-cell I-V curves from voltage 
ramps (-100/+150 mV) of TRPM8-wt and TRPM8-Y745H expressing HEK293 cells at 33°C in the presence and absence of A, 3 
μM BCTC; and B, 3 μM SKF96365. C, Summary histogram of experiments seen in A and B, showing the block of voltage-
evoked currents by BCTC and SKF96365 at a membrane potential of +120 mV. Statistical significance was assessed with the 
unpaired t-test: ** p < 0.01, n = 2-5.
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Molecular Pain 2009, 5:62 http://www.molecularpain.com/content/5/1/62Our results provide direct clues for the identification of
different structural motifs required for antagonist bind-
ing, aiding in the design of new candidate molecules for
specific inhibition of TRPM8 channels. They also provide
tools for current efforts to resolve the crystal structure of
TRP channels [43-45]. Further mutagenesis work is
required to identify the remaining binding site(s) of the
various TRPM8 blockers. One potential site is formed by
residues in the S2-S3 linker region, known to be impor-
tant for the sensitivity to icilin [42]. Another plausible
location is centred on residues within the TRP domain.
This domain is known to be important in the energetics of
channel opening, i.e. translating drug binding into chan-
nel opening [35,46,47]. In this regard, we consider a very
powerful approach to subject random generated libraries
of TRPM8 mutant channels [35] to the inhibitory actions
of the different antagonists characterized in this study. In
this way, one could obtain unbiased structural informa-
tion on the action of different inhibitors.
Finally, we also studied for the first time the inhibitory
capacity of two members of the imidazole family: the par-
ent compound itself, and the antimycotic agent econa-
zole, at the cooling-activated TRPM8 channel. Imidazole
was unable to inhibit neither of the two TRPM8 con-
structs, while econazole, similarly to its relative clotrima-
zole, proved to be a potent antagonist of the wild-type
channel. Both econazole and clotrimazole lost potency at
the Y745H mutant channel. This identification of a novel
TRPM8 antagonist prompts further screening of imida-
zole-based compounds in the quest for new TRPM8
blockers, and offers indications for the design of more
potent derivatives.
Conclusion
In this report, we identify, for the first time, structural ele-
ments on the TRPM8 protein that are critical for channel
antagonism, and demonstrate an important difference in
the way antagonists interact with the menthol binding site
of TRPM8. The results of this study provide valuable infor-
mation for solving the TRPM8 channel structure as well as
for the future design of new, specific modulator com-
pounds that could be useful in the treatment of cold-
evoked pain.
Methods
Generation of point-mutant TRPM8-Y745H
The full length cDNA encoding mouse TRPM8
(NM_134252) in pcDNA5 (Invitrogen) was kindly pro-
vided by Dr. Ardem Patapoutian, (Scripps Research Insti-
tute, La Jolla, CA). The TRPM8-Y745H mutant was
obtained by site-directed mutagenesis with the following
Molecular modelling of ligand docking into the putative menthol binding site of the TRPM8 receptorFigure 8
Molecular modelling of ligand docking into the putative menthol binding site of the TRPM8 receptor. Parts of 
the S1-S4 domains of TRPM8 are depicted and residues Y745 in S2 and N799 and D802 in S3 are highlighted. A, Menthol makes 
a hydrogen bond with Y745 (S2), disrupting its interaction with D802 (S3). B, BCTC is located externally of Y745 preventing 
the interaction with this residue. C, SKF96365 interacts with Y745 and N799, stabilizing the positions of the S2 and S3 domains. 
The TRPM8 model was built using the coordinates of Pedretti et al. [38].
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Molecular Pain 2009, 5:62 http://www.molecularpain.com/content/5/1/62primers: (for) 5'-CGTGGTCTTCCACATCGCC-3'; (rev) 5'-
GGCGATGTGGAAGACCACG-3', and Pfu Turbo Taq DNA
Polymerase (Roche).
Cell culture and transfection
HEK293 cells were cultured in DMEM containing 10% of
foetal bovine serum and antibiotics, and plated in 2 cm2
wells at 400.000-500.000 cells/well. 20-24 h after plating,
the cells were co-transfected with eGFP (0.3 μg/well) and
TRPM8-wt or TRPM8-Y745H (2 μg/well) by incubating
them with a solution containing the plasmid DNA and
Lipofectamine 2000 (Invitrogen) for 5 hours. Subse-
quently, the cells were trypsinized and replated on poly-L-
lysine-coated round coverslips (6 mm diameter). 20-48 h
post-transfection, GFP(+) cells were selected for calcium
imaging or electrophysiology experiments.
Calcium imaging
Prior to experiment, HEK293 cells transfected with the
TRPM8-wt/Y745H constructs were incubated with 5 μM
Fura-2AM dissolved in the bath solution and 0.02%
Pluronic (both from Invitrogen) for 40 min at 37°C in
darkness. Fluorescence measurements were made with a
Leica DM IRE2 inverted microscope fitted with a CCD
camera (Imago QE Sensicam, TillPhotonics, Graefelfing,
Germany). Fura-2 was excited at 340 nm and 380 nm with
a Polychrome IV monochromator (Till Photonics) and
the emitted fluorescence was filtered with a 510 nm long-
pass filter. Calibrated ratios were displayed online with
Till Vision software v4.01 (TillPhotonics). The bath solu-
tion in calcium imaging experiments, from here on
referred to as "control solution", contained (in mM): 140
NaCl, 3 KCl, 2.4 CaCl2, 1.3 MgCl2, 10 HEPES and 10 glu-
cose, and was adjusted to a pH of 7.4 with NaOH.
Electrophysiology
Whole-cell voltage-clamp recordings of TRPM8-wt/
Y745H transfected HEK293 cells were performed simulta-
neously with temperature recordings. Current develop-
ment was monitored at a holding potential of -60 mV. For
information on voltage-dependent effects, 1.25-s-dura-
tion voltage ramps from -100 to +150 mV were delivered
at desired time points. Standard patch-pipettes (3-5 MΩ)
were made of borosilicate glass capillaries (Harvard Appa-
ratus Ltd, UK), and contained (in mM): 150 NaCl, 3
MgCl2, 5 EGTA, 10 HEPES, (278 mOsm/kg; pH 7.2,
adjusted with NaOH). During electrophysiological
recordings, a divalent cation -free bath solution was used
to minimize desensitization, which contained: 150 NaCl,
10 EDTA, 10 HEPES and 10 glucose (pH 7.4 with NaOH).
The divalent-free solution was used in the preparation of
all chemical modulator containing solutions. Current sig-
nals were recorded with an Axopatch 200B patch-clamp
amplifier (Molecular Devices, Sunnyvale, CA, U.S.A.)
applying series resistance compensation (60-90%). Stim-
ulus delivery and data acquisition were performed using
pClamp 9 software (Molecular Devices). Data were sam-
pled at 5 kHz (ramps) and 1 kHz (timecourse) and filtered
online at 2 kHz.
Temperature stimulation
Coverslip pieces with cultured cells were placed in a
microchamber and continuously perfused with solutions
warmed at 33°C. The temperature was adjusted with a
water-cooled Peltier device placed at the inlet of the cham-
ber, and controlled by a feedback device. Cold-sensitivity
was investigated with a temperature decrease to 18-20°C
(Figure 1B).
Chemical modulators
The chemical substances studied for their modulatory
effect on the TRPM8 constructs were the cooling agent L-
menthol (Scharlau, Spain), and the antagonists SKF96365
(1- [2-(4-methoxyphenyl)-2-[3-(4-methoxyphenyl)pro-
poxy]ethyl-1H-imidazole; Tocris Bioscience, Bristol, UK);
clotrimazole (1- [(2-chlorophenyl)diphenylmethyl]-1H-
imidazole, Sigma), econazole (1- [2-[(4-chlorophe-
nyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imida-
zole, Sigma), imidazole (1,3-diazacyclopenta-2,4-diene,
Sigma), capsazepine (N- [2-(4-Chlorophenyl)ethyl]-
1,3,4,5-tetrahydro-7,8-dihydroxy-2H-2-benzazepine-2-
carbothioamide, Sigma); and BCTC (4- [3-chloro-pyridin-
2-yl]-piperazine-1-carboxylic acid [4-tert-butyl-phenyl]-
amide), which was a kind gift from Grünenthal GmbH
Aachen, Germany. ACD/ChemSketch Freeware, version
8.0 (Advanced Chemistry Development, Inc., Toronto,
ON, Canada, http://www.acdlabs.com) was used to draw
the structures of the various modulators shown in Figure
3.
Experimental protocols and interpretation of results
Experiments were always performed in parallel with cells
expressing TRPM8-wt and TRPM8-Y745H to minimize
any day-to-day variability in experimental conditions. To
estimate the shifts in the voltage-dependence of activation
of TRPM8-wt/Y745H in HEK293 cells, current-voltage (I-
V) relationships from voltage ramps were fitted with an
equation that combines a linear conductance multiplied
by a Boltzmann activation term [48]:
where g is the maximum whole-cell conductance, Erev is
the reversal potential, V1/2 is the potential for half maxi-
mal activation and s is the slope factor. For each cell, fit-
ting was started by analyzing a condition exhibiting
inward current. The value obtained for the parameter Erev
at this condition was used when fitting I-V curves that
lacked inward current.
I g E V V srev= − + − −*( ) /( exp[ ( ) / ])/V 1 1 2Page 11 of 13
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Molecular Pain 2009, 5:62 http://www.molecularpain.com/content/5/1/62Molecular modelling
TRPM8-ligand complexes were built using the TRPM8
model constructed by Pedretti et al. [38]. Ligand structures
were downloaded from the PubChem compound NCBI
component database http://pubchem.ncbi.nlm.nih.gov/
and used with no additional optimization. The protein-
ligand docking and the analysis of interactions was
accomplished with Autodock [49] implemented in the
general purpose molecular modelling software Yasara
[50], and optimized with AMBER 99 force field [51].
Docking trials were optimized and clustered to remove
redundancy and sorted by binding energy. Figures were
drawn with Pymol (DeLano Scientific, Palo Alto, Califor-
nia, USA. http://www.pymol.org).
Western blot
A TRPM8 antibody was generated in the laboratory.
Briefly, whole serum anti-TRPM8 was obtained by rabbit
immunization with a peptide corresponding to amino
acids 1-10 of mouse TRPM8 (MSFEGARLSM) conjugated
to keyhole limpet hemocyanin. For immunoblot analysis
of TRPM8-wt/Y745H transfected HEK293 cells, 48-h post
transfection, cells were mixed with sample buffer (4%
SDS (w/v); 10% glycerol (v/v); 4% 2-mercaptoethanol;
0.2% bromophenol blue (w/v); 50 mM Tris-HCl; pH 6.8),
heated at 95°C for 5 min, and then subjected to SDS-
PAGE gel electrophoresis (10% acrylamide gel). Proteins
were transferred onto a nitro-cellulose membrane
Hybond™ ECL (Amersham Biosciences). Membranes were
blocked with 10% non-fat milk in TBS (Tris-buffered
saline), and subsequently incubated with the primary
antibody for TRPM8 at 1:500 dilution for 1 h at room
temperature and at 4°C overnight. Blots were treated with
peroxidase-conjugated goat anti-rabbit IgG at 1:2000
dilution for 1 h, and protein signals were revealed using
the ECL Advance™ Western Blotting Detection Kit (Amer-
sham Biosciences) and visualized with the LAS-1000
imaging system by Fujifilm.
Data analysis
Data are reported as mean ± standard error of the mean.
All fitting was carried out with the Levenberg-Marquardt
method implemented in the Origin 7.0 software. In the
dose-inhibition curves shown in Figure 5, error bars were
used as weights in fits to the Hill equation. When compar-
ing two means, statistical significance (p < 0.05) was
assessed by Student's two-tailed t-test. For multiple com-
parisons of means, one-way or two-way ANOVA was per-
formed using GraphPad Prism version 4.00 for Windows
(GraphPad Software, San Diego California USA, http://
www.graphpad.com). Paired or repeated-measures tests
were used where appropriate to account for inter-individ-
ual variability.
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